Loading…
Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir
Objective: Amyloid beta (Aβ) positron emission tomography (PET) imaging helps estimate Aβ neuritic plaque density in patients with cognitive impairment who are under evaluation for Alzheimer's disease (AD). This study aims to evaluate the cost-effectiveness of the Aβ-PET scan as an adjunct to s...
Saved in:
Published in: | Current medical research and opinion 2017-04, Vol.33 (4), p.675-685 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c413t-24bbc28603599f189360766e7cb994606da4f750fab35962c6dd3ff1bcae47083 |
---|---|
cites | cdi_FETCH-LOGICAL-c413t-24bbc28603599f189360766e7cb994606da4f750fab35962c6dd3ff1bcae47083 |
container_end_page | 685 |
container_issue | 4 |
container_start_page | 675 |
container_title | Current medical research and opinion |
container_volume | 33 |
creator | Hornberger, John Bae, Jay Watson, Ian Johnston, Joe Happich, Michael |
description | Objective: Amyloid beta (Aβ) positron emission tomography (PET) imaging helps estimate Aβ neuritic plaque density in patients with cognitive impairment who are under evaluation for Alzheimer's disease (AD). This study aims to evaluate the cost-effectiveness of the Aβ-PET scan as an adjunct to standard diagnostic assessment for diagnosis of AD in France, using florbetapir as an example.
Methods: A state-transition probability analysis was developed adopting the French Health Technology Assessment (HTA) perspective per guidance. Parameters included test characteristics, rate of cognitive decline, treatment effect, costs, and quality of life. Additional scenarios assessed the validity of the analytical framework, including: (1) earlier evaluation/treatment; (2) cerebrospinal fluid (CSF) as a comparator; and (3) use of other diagnostic procedures. Outputs included differences in quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). All benefits and costs were discounted for time preferences. Sensitivity analyses were performed to assess the robustness of findings and key influencers of outcomes.
Results: Aβ-PET used as an adjunct to standard diagnostic assessment increased QALYs by 0.021 years and 10 year costs by €470 per patient. The ICER was €21,888 per QALY gained compared to standard diagnostic assessment alone. When compared with CSF, Aβ-PET costs €24,084 per QALY gained. In other scenarios, Aβ-PET was consistently cost-effective relative to the commonly used affordability threshold (€40,000 per QALY). Over 95% of simulations in the sensitivity analysis were cost-effective.
Conclusion: Aβ-PET is projected to affordably increase QALYs from the French HTA perspective per guidance over a range of clinical scenarios, comparators, and input parameters. |
doi_str_mv | 10.1080/03007995.2016.1277197 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1854614549</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1854614549</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-24bbc28603599f189360766e7cb994606da4f750fab35962c6dd3ff1bcae47083</originalsourceid><addsrcrecordid>eNp9kctuEzEYhS0EomnhEai8g80Ee8bjy44qohcpEhtYWx5fElee8WA7qtIH4jnxKCkSm65s-Xz_f3R8APiE0Rojjr6iDiEmRL9uEaZr3DKGBXsDVpiwriGcsbdgtTDNAl2Ay5wfEcItF-I9uGg56npO2hX4swl-8loFqCYDdcwF-nEO9aX4OGUYHVTjMURv4GCLgsYWqxcJPvmy_1-bY_YlVcmOPueFKXGMu6Tm_bFuVTs_7aCvskrhCG_C89760abPGRqfrcoWNrDsLdTLtRq7ENOyePbpA3jnVMj24_m8Ar9uv__c3DfbH3cPm5ttownuStOSYdAtpzWdEA5z0VHEKLVMD0IQiqhRxLEeOTVUgraaGtM5hwetLGGId1fgy2nvnOLvg81F1ijahqAmGw9ZYt4TiklPREX7E6pTzDlZJ-dUQ6ajxEguFcmXiuRSkTxXVOeuzxaHYbTm39RLJxX4dgL85GIa1VNMwcii6k8nl9SkfZbd6x5_AXoEo3o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1854614549</pqid></control><display><type>article</type><title>Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Hornberger, John ; Bae, Jay ; Watson, Ian ; Johnston, Joe ; Happich, Michael</creator><creatorcontrib>Hornberger, John ; Bae, Jay ; Watson, Ian ; Johnston, Joe ; Happich, Michael</creatorcontrib><description>Objective: Amyloid beta (Aβ) positron emission tomography (PET) imaging helps estimate Aβ neuritic plaque density in patients with cognitive impairment who are under evaluation for Alzheimer's disease (AD). This study aims to evaluate the cost-effectiveness of the Aβ-PET scan as an adjunct to standard diagnostic assessment for diagnosis of AD in France, using florbetapir as an example.
Methods: A state-transition probability analysis was developed adopting the French Health Technology Assessment (HTA) perspective per guidance. Parameters included test characteristics, rate of cognitive decline, treatment effect, costs, and quality of life. Additional scenarios assessed the validity of the analytical framework, including: (1) earlier evaluation/treatment; (2) cerebrospinal fluid (CSF) as a comparator; and (3) use of other diagnostic procedures. Outputs included differences in quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). All benefits and costs were discounted for time preferences. Sensitivity analyses were performed to assess the robustness of findings and key influencers of outcomes.
Results: Aβ-PET used as an adjunct to standard diagnostic assessment increased QALYs by 0.021 years and 10 year costs by €470 per patient. The ICER was €21,888 per QALY gained compared to standard diagnostic assessment alone. When compared with CSF, Aβ-PET costs €24,084 per QALY gained. In other scenarios, Aβ-PET was consistently cost-effective relative to the commonly used affordability threshold (€40,000 per QALY). Over 95% of simulations in the sensitivity analysis were cost-effective.
Conclusion: Aβ-PET is projected to affordably increase QALYs from the French HTA perspective per guidance over a range of clinical scenarios, comparators, and input parameters.</description><identifier>ISSN: 0300-7995</identifier><identifier>EISSN: 1473-4877</identifier><identifier>DOI: 10.1080/03007995.2016.1277197</identifier><identifier>PMID: 28035842</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Alzheimer disease ; Alzheimer Disease - diagnostic imaging ; Alzheimer Disease - economics ; amyloid beta peptides ; Amyloid beta-Peptides - analysis ; Amyloid beta-Peptides - metabolism ; Aniline Compounds - therapeutic use ; Cost-Benefit Analysis ; diagnosis ; diagnostic imaging ; Ethylene Glycols - therapeutic use ; Fluorine Radioisotopes - therapeutic use ; Humans ; positron-emission tomography ; Positron-Emission Tomography - economics ; Positron-Emission Tomography - methods ; Predictive Value of Tests</subject><ispartof>Current medical research and opinion, 2017-04, Vol.33 (4), p.675-685</ispartof><rights>2017 Informa UK Limited, trading as Taylor & Francis Group 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-24bbc28603599f189360766e7cb994606da4f750fab35962c6dd3ff1bcae47083</citedby><cites>FETCH-LOGICAL-c413t-24bbc28603599f189360766e7cb994606da4f750fab35962c6dd3ff1bcae47083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28035842$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hornberger, John</creatorcontrib><creatorcontrib>Bae, Jay</creatorcontrib><creatorcontrib>Watson, Ian</creatorcontrib><creatorcontrib>Johnston, Joe</creatorcontrib><creatorcontrib>Happich, Michael</creatorcontrib><title>Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir</title><title>Current medical research and opinion</title><addtitle>Curr Med Res Opin</addtitle><description>Objective: Amyloid beta (Aβ) positron emission tomography (PET) imaging helps estimate Aβ neuritic plaque density in patients with cognitive impairment who are under evaluation for Alzheimer's disease (AD). This study aims to evaluate the cost-effectiveness of the Aβ-PET scan as an adjunct to standard diagnostic assessment for diagnosis of AD in France, using florbetapir as an example.
Methods: A state-transition probability analysis was developed adopting the French Health Technology Assessment (HTA) perspective per guidance. Parameters included test characteristics, rate of cognitive decline, treatment effect, costs, and quality of life. Additional scenarios assessed the validity of the analytical framework, including: (1) earlier evaluation/treatment; (2) cerebrospinal fluid (CSF) as a comparator; and (3) use of other diagnostic procedures. Outputs included differences in quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). All benefits and costs were discounted for time preferences. Sensitivity analyses were performed to assess the robustness of findings and key influencers of outcomes.
Results: Aβ-PET used as an adjunct to standard diagnostic assessment increased QALYs by 0.021 years and 10 year costs by €470 per patient. The ICER was €21,888 per QALY gained compared to standard diagnostic assessment alone. When compared with CSF, Aβ-PET costs €24,084 per QALY gained. In other scenarios, Aβ-PET was consistently cost-effective relative to the commonly used affordability threshold (€40,000 per QALY). Over 95% of simulations in the sensitivity analysis were cost-effective.
Conclusion: Aβ-PET is projected to affordably increase QALYs from the French HTA perspective per guidance over a range of clinical scenarios, comparators, and input parameters.</description><subject>Alzheimer disease</subject><subject>Alzheimer Disease - diagnostic imaging</subject><subject>Alzheimer Disease - economics</subject><subject>amyloid beta peptides</subject><subject>Amyloid beta-Peptides - analysis</subject><subject>Amyloid beta-Peptides - metabolism</subject><subject>Aniline Compounds - therapeutic use</subject><subject>Cost-Benefit Analysis</subject><subject>diagnosis</subject><subject>diagnostic imaging</subject><subject>Ethylene Glycols - therapeutic use</subject><subject>Fluorine Radioisotopes - therapeutic use</subject><subject>Humans</subject><subject>positron-emission tomography</subject><subject>Positron-Emission Tomography - economics</subject><subject>Positron-Emission Tomography - methods</subject><subject>Predictive Value of Tests</subject><issn>0300-7995</issn><issn>1473-4877</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kctuEzEYhS0EomnhEai8g80Ee8bjy44qohcpEhtYWx5fElee8WA7qtIH4jnxKCkSm65s-Xz_f3R8APiE0Rojjr6iDiEmRL9uEaZr3DKGBXsDVpiwriGcsbdgtTDNAl2Ay5wfEcItF-I9uGg56npO2hX4swl-8loFqCYDdcwF-nEO9aX4OGUYHVTjMURv4GCLgsYWqxcJPvmy_1-bY_YlVcmOPueFKXGMu6Tm_bFuVTs_7aCvskrhCG_C89760abPGRqfrcoWNrDsLdTLtRq7ENOyePbpA3jnVMj24_m8Ar9uv__c3DfbH3cPm5ttownuStOSYdAtpzWdEA5z0VHEKLVMD0IQiqhRxLEeOTVUgraaGtM5hwetLGGId1fgy2nvnOLvg81F1ijahqAmGw9ZYt4TiklPREX7E6pTzDlZJ-dUQ6ajxEguFcmXiuRSkTxXVOeuzxaHYbTm39RLJxX4dgL85GIa1VNMwcii6k8nl9SkfZbd6x5_AXoEo3o</recordid><startdate>20170403</startdate><enddate>20170403</enddate><creator>Hornberger, John</creator><creator>Bae, Jay</creator><creator>Watson, Ian</creator><creator>Johnston, Joe</creator><creator>Happich, Michael</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170403</creationdate><title>Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir</title><author>Hornberger, John ; Bae, Jay ; Watson, Ian ; Johnston, Joe ; Happich, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-24bbc28603599f189360766e7cb994606da4f750fab35962c6dd3ff1bcae47083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Alzheimer disease</topic><topic>Alzheimer Disease - diagnostic imaging</topic><topic>Alzheimer Disease - economics</topic><topic>amyloid beta peptides</topic><topic>Amyloid beta-Peptides - analysis</topic><topic>Amyloid beta-Peptides - metabolism</topic><topic>Aniline Compounds - therapeutic use</topic><topic>Cost-Benefit Analysis</topic><topic>diagnosis</topic><topic>diagnostic imaging</topic><topic>Ethylene Glycols - therapeutic use</topic><topic>Fluorine Radioisotopes - therapeutic use</topic><topic>Humans</topic><topic>positron-emission tomography</topic><topic>Positron-Emission Tomography - economics</topic><topic>Positron-Emission Tomography - methods</topic><topic>Predictive Value of Tests</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hornberger, John</creatorcontrib><creatorcontrib>Bae, Jay</creatorcontrib><creatorcontrib>Watson, Ian</creatorcontrib><creatorcontrib>Johnston, Joe</creatorcontrib><creatorcontrib>Happich, Michael</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current medical research and opinion</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hornberger, John</au><au>Bae, Jay</au><au>Watson, Ian</au><au>Johnston, Joe</au><au>Happich, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir</atitle><jtitle>Current medical research and opinion</jtitle><addtitle>Curr Med Res Opin</addtitle><date>2017-04-03</date><risdate>2017</risdate><volume>33</volume><issue>4</issue><spage>675</spage><epage>685</epage><pages>675-685</pages><issn>0300-7995</issn><eissn>1473-4877</eissn><abstract>Objective: Amyloid beta (Aβ) positron emission tomography (PET) imaging helps estimate Aβ neuritic plaque density in patients with cognitive impairment who are under evaluation for Alzheimer's disease (AD). This study aims to evaluate the cost-effectiveness of the Aβ-PET scan as an adjunct to standard diagnostic assessment for diagnosis of AD in France, using florbetapir as an example.
Methods: A state-transition probability analysis was developed adopting the French Health Technology Assessment (HTA) perspective per guidance. Parameters included test characteristics, rate of cognitive decline, treatment effect, costs, and quality of life. Additional scenarios assessed the validity of the analytical framework, including: (1) earlier evaluation/treatment; (2) cerebrospinal fluid (CSF) as a comparator; and (3) use of other diagnostic procedures. Outputs included differences in quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). All benefits and costs were discounted for time preferences. Sensitivity analyses were performed to assess the robustness of findings and key influencers of outcomes.
Results: Aβ-PET used as an adjunct to standard diagnostic assessment increased QALYs by 0.021 years and 10 year costs by €470 per patient. The ICER was €21,888 per QALY gained compared to standard diagnostic assessment alone. When compared with CSF, Aβ-PET costs €24,084 per QALY gained. In other scenarios, Aβ-PET was consistently cost-effective relative to the commonly used affordability threshold (€40,000 per QALY). Over 95% of simulations in the sensitivity analysis were cost-effective.
Conclusion: Aβ-PET is projected to affordably increase QALYs from the French HTA perspective per guidance over a range of clinical scenarios, comparators, and input parameters.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>28035842</pmid><doi>10.1080/03007995.2016.1277197</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0300-7995 |
ispartof | Current medical research and opinion, 2017-04, Vol.33 (4), p.675-685 |
issn | 0300-7995 1473-4877 |
language | eng |
recordid | cdi_proquest_miscellaneous_1854614549 |
source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
subjects | Alzheimer disease Alzheimer Disease - diagnostic imaging Alzheimer Disease - economics amyloid beta peptides Amyloid beta-Peptides - analysis Amyloid beta-Peptides - metabolism Aniline Compounds - therapeutic use Cost-Benefit Analysis diagnosis diagnostic imaging Ethylene Glycols - therapeutic use Fluorine Radioisotopes - therapeutic use Humans positron-emission tomography Positron-Emission Tomography - economics Positron-Emission Tomography - methods Predictive Value of Tests |
title | Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T19%3A20%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20and%20cost%20implications%20of%20amyloid%20beta%20detection%20with%20amyloid%20beta%20positron%20emission%20tomography%20imaging%20in%20early%20Alzheimer's%20disease%20-%20the%20case%20of%20florbetapir&rft.jtitle=Current%20medical%20research%20and%20opinion&rft.au=Hornberger,%20John&rft.date=2017-04-03&rft.volume=33&rft.issue=4&rft.spage=675&rft.epage=685&rft.pages=675-685&rft.issn=0300-7995&rft.eissn=1473-4877&rft_id=info:doi/10.1080/03007995.2016.1277197&rft_dat=%3Cproquest_cross%3E1854614549%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c413t-24bbc28603599f189360766e7cb994606da4f750fab35962c6dd3ff1bcae47083%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1854614549&rft_id=info:pmid/28035842&rfr_iscdi=true |